Last reviewed · How we verify

Avastin intravitreal injection

Ophthalmological Association Edelweiss · Phase 3 active Small molecule

Avastin intravitreal injection is a VEGF inhibitor (monoclonal antibody) Small molecule drug developed by Ophthalmological Association Edelweiss. It is currently in Phase 3 development for Diabetic macular edema, Retinal vein occlusion (branch and central), Age-related macular degeneration (wet/neovascular). Also known as: Avastin.

Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.

Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye. Used for Diabetic macular edema, Retinal vein occlusion (branch and central), Age-related macular degeneration (wet/neovascular).

At a glance

Generic nameAvastin intravitreal injection
Also known asAvastin
SponsorOphthalmological Association Edelweiss
Drug classVEGF inhibitor (monoclonal antibody)
TargetVEGF (Vascular Endothelial Growth Factor)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

When administered as an intravitreal injection, bevacizumab binds to and neutralizes VEGF, a key driver of pathological neovascularization in retinal diseases. By reducing VEGF signaling, the drug suppresses the growth of abnormal blood vessels and reduces vascular permeability, thereby reducing retinal edema and preventing vision loss in conditions characterized by excessive angiogenesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Avastin intravitreal injection

What is Avastin intravitreal injection?

Avastin intravitreal injection is a VEGF inhibitor (monoclonal antibody) drug developed by Ophthalmological Association Edelweiss, indicated for Diabetic macular edema, Retinal vein occlusion (branch and central), Age-related macular degeneration (wet/neovascular).

How does Avastin intravitreal injection work?

Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.

What is Avastin intravitreal injection used for?

Avastin intravitreal injection is indicated for Diabetic macular edema, Retinal vein occlusion (branch and central), Age-related macular degeneration (wet/neovascular), Proliferative diabetic retinopathy.

Who makes Avastin intravitreal injection?

Avastin intravitreal injection is developed by Ophthalmological Association Edelweiss (see full Ophthalmological Association Edelweiss pipeline at /company/ophthalmological-association-edelweiss).

Is Avastin intravitreal injection also known as anything else?

Avastin intravitreal injection is also known as Avastin.

What drug class is Avastin intravitreal injection in?

Avastin intravitreal injection belongs to the VEGF inhibitor (monoclonal antibody) class. See all VEGF inhibitor (monoclonal antibody) drugs at /class/vegf-inhibitor-monoclonal-antibody.

What development phase is Avastin intravitreal injection in?

Avastin intravitreal injection is in Phase 3.

What are the side effects of Avastin intravitreal injection?

Common side effects of Avastin intravitreal injection include Endophthalmitis, Retinal detachment, Cataract progression, Intraocular pressure elevation, Floaters/vitreous opacities.

What does Avastin intravitreal injection target?

Avastin intravitreal injection targets VEGF (Vascular Endothelial Growth Factor) and is a VEGF inhibitor (monoclonal antibody).

Related